Cancer Guidelines Name Adaptive's clonoSEQ Testing
NCCN myeloma guidelines now name clonoSEQ and add annual maintenance testing. Adaptive's MRD revenue guidance stands at $268M-$278M. Adoption is the test.
Topic
Adaptive Biotechnologies
Topic
Topic
Topic
NCCN myeloma guidelines now name clonoSEQ and add annual maintenance testing. Adaptive's MRD revenue guidance stands at $268M-$278M. Adoption is the test.